New Alzheimer Drugs on the Horizon!
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Aducanumab is a pi<strong>on</strong>eer in <strong>the</strong> fight against AD. To date, <strong>the</strong>re have been no o<strong>the</strong>r<br />
medicati<strong>on</strong>s that destroy brain plaques. Current drugs decelerate <strong>the</strong> disease process<br />
temporarily but are unable to halt completely its progressi<strong>on</strong>. Aducanumab<br />
significantly retards plaque formati<strong>on</strong>.<br />
The drug is <strong>the</strong> brainchild of <strong>the</strong> Biogen company, based in Massachusetts. Clinical<br />
testing is in <strong>the</strong> final Phase 3 stage. This segment of evaluati<strong>on</strong> involves a large study<br />
group of 1,350 patients over five years. Thorough testing <strong>on</strong> a broad scale is required<br />
before <strong>the</strong> drug can be marketed. Analysts expect that within three years, <strong>the</strong> data will<br />
indicate whe<strong>the</strong>r Adu can mab is <strong>the</strong> "Goldilocks" drug, <strong>the</strong> "just right" formulati<strong>on</strong><br />
that will resolve AD. Researchers are optimistic regarding <strong>the</strong> drug's potential.
![Projected Senior Populations in the State of Ohio [Infographic]](https://img.yumpu.com/54840652/1/190x107/projected-senior-populations-in-the-state-of-ohio-infographic.jpg?quality=85)
Change language